A detailed history of Vestcor Inc transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Vestcor Inc holds 20,208 shares of NBIX stock, worth $2.37 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares
20,208
Previous 25,092 19.46%
Holding current value
$2.37 Million
Previous $3.45 Million 32.6%
% of portfolio
0.07%
Previous 0.12%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024

SELL
$114.58 - $153.15 $559,608 - $747,984
-4,884 Reduced 19.46%
20,208 $2.33 Million
Q1 2024

May 14, 2024

SELL
$130.4 - $143.74 $33,643 - $37,084
-258 Reduced 1.02%
25,092 $3.46 Million
Q4 2023

Feb 14, 2024

BUY
$106.07 - $132.76 $104,054 - $130,237
981 Added 4.03%
25,350 $3.34 Million
Q3 2023

Nov 14, 2023

BUY
$94.02 - $117.1 $670,174 - $834,688
7,128 Added 41.34%
24,369 $2.74 Million
Q2 2023

Aug 15, 2023

BUY
$89.53 - $104.87 $340,124 - $398,401
3,799 Added 28.26%
17,241 $1.63 Million
Q4 2022

Feb 15, 2023

BUY
$106.72 - $127.06 $685,782 - $816,487
6,426 Added 91.59%
13,442 $1.61 Million
Q3 2022

Nov 14, 2022

BUY
$92.03 - $107.81 $441,744 - $517,488
4,800 Added 216.61%
7,016 $745,000
Q2 2022

Aug 15, 2022

BUY
$75.79 - $100.07 $54,265 - $71,650
716 Added 47.73%
2,216 $216,000
Q1 2022

May 16, 2022

SELL
$72.45 - $94.81 $137,365 - $179,759
-1,896 Reduced 55.83%
1,500 $141,000
Q4 2021

Feb 15, 2022

SELL
$79.65 - $106.22 $38,391 - $51,198
-482 Reduced 12.43%
3,396 $289,000
Q3 2021

Nov 15, 2021

SELL
$86.18 - $99.03 $15,340 - $17,627
-178 Reduced 4.39%
3,878 $372,000
Q2 2021

Aug 16, 2021

BUY
$89.43 - $102.27 $141,031 - $161,279
1,577 Added 63.61%
4,056 $395,000
Q2 2020

Aug 14, 2020

BUY
$85.09 - $130.36 $210,938 - $323,162
2,479 New
2,479 $302,000

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $11.2B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Vestcor Inc Portfolio

Follow Vestcor Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vestcor Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vestcor Inc with notifications on news.